Company Name: Bionomics
Announcement Date: 03/10/2016
Announcement Category: Awards/recognition, Investment
Announcement Content:
Impressive results from Phase 2 clinical trials of BNC210 as a treatment for anxiety and depression presents a great opportunity for SA-based Bionomics, according to investment research platform Seeking Alpha.
Announcement URL: http://seekingalpha.com/article/4007852-bionomics-longer-depressed-opportunity-knocks
About Bionomics:
Bionomics is an Adelaide-based biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible.
Go to Company Profile for: Bionomics
Announcement Contact: [email protected]
